Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download NEOPLASIE GENITOURINARIE valutazione critica
Document related concepts
no text concepts found
Transcript
NEOPLASIE GENITOURINARIE valutazione critica PROSTATE CANCER Isabella Chiappino MD Dipartimento di Oncologia AOU Città della Salute e della Scienza Torino Clinical Trial Design and Chemotherapy Use in Prostate Cancer: Correcting Old Mistakes, Making New Ones Ian Tannock MD, PhD Abstract No: 5000 The Prostate Cancer Working Group 3 (PCWG3) Consensus for Trials in Castration-Resistant Prostate Cancer (CRPC). Howard I. Scher MD Abstract No: 5001 Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). Nicholas David James , MD, PhD Abstract No: LBA5002 A Phase III Protocol of Androgen Suppression and Radiotherapy vs. AS and RT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High Risk Prostate Cancer. Howard M. Sandler , MD Genomics as Classifiers and Predictors for Prostate Cancer: Implications for the Field. Scott Tomlins , MD,PhD Refining Androgen Deprivation Therapy: A Work in Progress Celestia S. Higano MD, FACP Abstract No: 5006 Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial— NCT00423475.Christian Carrie Abstract No: 5007 TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial. Gillian M. Duchesne Abstract No: 5008 Long-term Consequences of Intermittent and Continuous Androgen Deprivation in Men with Metastatic Prostate Cancer. Dawn L. Hershman Clinical Trial Design and Chemotherapy Use in Prostate Cancer: Correcting Old Mistakes, Making New Ones Ian Tannock MD, PhD 2013 2014 2015 Clinical Trial Design and Chemotherapy Use in Prostate Cancer: Correcting Old Mistakes, Making New Ones Ian Tannock MD, PhD Abstract No: 5000 The Prostate Cancer Working Group 3 (PCWG3) Consensus for Trials in Castration-Resistant Prostate Cancer (CRPC). Howard I. Scher MD Abstract No: 5001 Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). Nicholas David James , MD, PhD Abstract No: LBA5002 A Phase III Protocol of Androgen Suppression and Radiotherapy vs. AS and RT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High Risk Prostate Cancer. Howard M. Sandler , MD Genomics as Classifiers and Predictors for Prostate Cancer: Implications for the Field. Scott Tomlins , MD,PhD Refining Androgen Deprivation Therapy: A Work in Progress Celestia S. Higano MD, FACP Abstract No: 5006 Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial— NCT00423475.Christian Carrie Abstract No: 5007 TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial. Gillian M. Duchesne Abstract No: 5008 Long-term Consequences of Intermittent and Continuous Androgen Deprivation in Men with Metastatic Prostate Cancer. Dawn L. Hershman Refining Androgen Deprivation Therapy: A Work in Progress Celestia S. Higano MD, FACP Abstract No: 5006 Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial— NCT00423475.Christian Carrie Abstract No: 5007 TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial. Gillian M. Duchesne Abstract No: 5008 Long-term Consequences of Intermittent and Continuous Androgen Deprivation in Men with Metastatic Prostate Cancer. Dawn L. Hershman Refining Androgen Deprivation Therapy: A Work in Progress Celestia S. Higano MD, FACP Abstract No: 5006 Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial— NCT00423475.Christian Carrie Abstract No: 5007 TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial. Gillian M. Duchesne Abstract No: 5008 Long-term Consequences of Intermittent and Continuous Androgen Deprivation in Men with Metastatic Prostate Cancer. Dawn L. Hershman
![“Basic and translational oncology” [Selezionare la data] Italian](http://s1.studyres.com/store/data/003369983_1-0c2f97f3754c36ff0d6a75a322ab9225-150x150.png)
